📊 SUPN Key Takeaways
Is Supernus Pharmaceuticals, Inc.. (SUPN) a Good Investment?
Supernus Pharmaceuticals demonstrates strong financial health with zero debt, robust cash reserves ($184.9M), and exceptional free cash flow generation (32% FCF margin). However, the company is operationally unprofitable with deteriorating profitability trends (-152.2% YoY net income decline), offsetting balance sheet strength and warranting cautious observation until near-term profitability recovery is demonstrated.
Why Buy Supernus Pharmaceuticals, Inc.. Stock? SUPN Key Strengths
- Exceptional free cash flow generation of $66.5M with 32% FCF margin despite GAAP losses, indicating strong underlying economics
- Zero long-term debt with strong balance sheet: $184.9M cash, $1.1B equity, debt-to-equity of 0.0x
- Healthy liquidity position with 1.96x current ratio and 1.66x quick ratio, providing operational flexibility
- Revenue growth of 8.6% YoY demonstrates market demand for pharmaceutical products
- Substantial asset base of $1.5B provides financial cushion to weather industry cycles
SUPN Stock Risks: Supernus Pharmaceuticals, Inc.. Investment Risks
- Company is operationally unprofitable with -$8.3M operating income and deteriorating -$2.3M net income (-152.2% YoY decline)
- Negative operating margin (-4.0%) and net margin (-1.1%) concerning for pharma company at $207.7M revenue scale
- ROE and ROA both deeply negative (-0.2%), indicating value destruction from capital deployed
- Gap between positive FCF and GAAP losses suggests reliance on non-cash charges or working capital benefits; sustainability unclear
- 34 insider Form 4 filings in 90 days may indicate concern or defensive positioning by management
Key Metrics to Watch
- Operating Income and Operating Margin trends toward profitability
- Net Income and Net Margin trajectory - critical to confirm this is not structural decline
- Free Cash Flow sustainability - whether 32% FCF margin can persist long-term
- Revenue growth maintenance - can 8.6% growth continue without profitability improvements
- Cash balance depletion rate - determine runway given current burn dynamics
- Gross Margin (if disclosed) - understand pricing power and cost structure
Supernus Pharmaceuticals, Inc.. (SUPN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 32.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
SUPN Profit Margin, ROE & Profitability Analysis
SUPN vs Healthcare Sector: How Supernus Pharmaceuticals, Inc.. Compares
How Supernus Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Supernus Pharmaceuticals, Inc.. Stock Overvalued? SUPN Valuation Analysis 2026
Based on fundamental analysis, Supernus Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Supernus Pharmaceuticals, Inc.. Balance Sheet: SUPN Debt, Cash & Liquidity
SUPN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Supernus Pharmaceuticals, Inc..'s revenue has grown significantly by 38% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.02 reflects profitable operations.
SUPN Revenue Growth, EPS Growth & YoY Performance
SUPN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $149.8M | -$2.3M | $-0.04 |
| Q3 2025 | $175.7M | $124.0K | $-0.61 |
| Q2 2025 | $165.5M | $124.0K | $0.19 |
| Q1 2025 | $143.6M | $124.0K | $0.00 |
| Q3 2024 | $153.9M | $124.0K | $0.00 |
| Q2 2024 | $135.6M | $124.0K | $-0.02 |
| Q1 2024 | $143.6M | $124.0K | $0.00 |
| Q3 2023 | $153.9M | $141.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Supernus Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
SUPN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Supernus Pharmaceuticals, Inc.. (CIK: 0001356576)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SUPN
What is the AI rating for SUPN?
Supernus Pharmaceuticals, Inc.. (SUPN) has an AI rating of HOLD with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SUPN's key strengths?
Claude: Exceptional free cash flow generation of $66.5M with 32% FCF margin despite GAAP losses, indicating strong underlying economics. Zero long-term debt with strong balance sheet: $184.9M cash, $1.1B equity, debt-to-equity of 0.0x.
What are the risks of investing in SUPN?
Claude: Company is operationally unprofitable with -$8.3M operating income and deteriorating -$2.3M net income (-152.2% YoY decline). Negative operating margin (-4.0%) and net margin (-1.1%) concerning for pharma company at $207.7M revenue scale.
What is SUPN's revenue and growth?
Supernus Pharmaceuticals, Inc.. reported revenue of $207.7M.
Does SUPN pay dividends?
Supernus Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find SUPN SEC filings?
Official SEC filings for Supernus Pharmaceuticals, Inc.. (CIK: 0001356576) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SUPN's EPS?
Supernus Pharmaceuticals, Inc.. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SUPN a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Supernus Pharmaceuticals, Inc.. has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SUPN stock overvalued or undervalued?
Valuation metrics for SUPN: ROE of -0.2% (sector avg: 15%), net margin of -1.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SUPN stock in 2026?
Our dual AI analysis gives Supernus Pharmaceuticals, Inc.. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SUPN's free cash flow?
Supernus Pharmaceuticals, Inc..'s operating cash flow is $66.5M, with capital expenditures of $0.0. FCF margin is 32.0%.
How does SUPN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1.1% (avg: 12%), ROE -0.2% (avg: 15%), current ratio 1.96 (avg: 2).